Physician profile
Stephen J Pollard
NPI 1629077698
$301,010.19
in general payments reported to CMS, 2019-2025
31 companies · $26K in 2025
The $26K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $18K · 2021: $28K · 2022: $43K · 2023: $70K · 2024: $39K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Food and Beverage: $5,871 · Travel and Lodging: $5,282 · Consulting Fee: $2,180 · Education: $91.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,242.80 |
| Food and Beverage | $5,871.04 |
| Travel and Lodging | $5,282.07 |
| Consulting Fee | $2,180.00 |
| Education | $91.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $130,734.26 | 2019-2025 | Dupixent |
| Genzyme Corporation | $88,768.51 | 2020-2025 | |
| Glaxosmithkline, LLC. | $67,937.91 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genentech USA, INC. | $4,783.71 | 2019-2025 | Xolair |
| Biocryst Pharmaceuticals, INC. | $2,650.22 | 2019 | |
| Incyte Corporation | $2,354.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,823.39 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $358.17 | 2019-2023 | Hizentra, Haegarda |
| Amgen INC. | $287.19 | 2023-2025 | Tezspire |
| Optinose US, INC. | $164.21 | 2019-2024 | |
| Pfizer INC. | $149.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $143.66 | 2019-2025 | |
| Pharming Healthcare, INC. | $134.69 | 2023-2025 | Joenja, Ruconest |
| Kaleo, INC. | $113.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.30 | 2021-2023 | Cuvitru, Takhzyro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $84.02 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $70.83 | 2024-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $70.60 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.30 | 2022 | |
| Ionis Pharmaceuticals, INC. | $42.63 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $35.25 | 2022 | |
| Abbvie INC. | $33.00 | 2024 | |
| Circassia INC. | $29.93 | 2019 | |
| Shire North American Group INC | $23.38 | 2019 | |
| Octapharma USA, INC. | $19.85 | 2023 | Panzyga |
| Merck Sharp & Dohme LLC | $16.33 | 2021 | |
| Hikma Pharmaceuticals USA | $14.72 | 2024 | Ryaltris |
| Grifols USA, LLC | $14.46 | 2025 | Xembify |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.